The Food and Drug Administration last week updated 2017 draft guidance to clarify the categories of clinical and decision support software subject to FDA oversight under the 21st Century Cures Act based on risk, and released final guidance on the types of software no longer considered medical devices under the Act’s amended definition of device. “We’re making clear that certain digital health technologies — such as mobile apps that are intended only for maintaining or encouraging a healthy lifestyle — generally fall outside the scope of the FDA’s regulation,” said Principal Deputy Commissioner Abernethy, M.D. “Such technologies tend to pose a low risk to patients, but can provide great value to consumers and the health care system.”

Related News Articles

Headline
The House Energy and Commerce Committee Sept. 18 advanced legislation on expiring telehealth and hospital-at-home flexibilities. The AHA supported the passage…
Headline
Sens. Chuck Schumer, D-N.Y., Susan Collins, R-Maine, and Bob Casey, D-Pa., Sept. 11 introduced the SEPSIS Act, legislation which would task the Centers for…
Headline
The House Education and Workforce Committee advanced several bills Sept. 11, including legislation that would empower commercial insurance companies at the…
Perspective
Congress returns to Washington, D.C., next week following the summer recess, and lawmakers can expect a busy fall as they face a full plate of issues that need…
Headline
The Senate Appropriations Committee Aug. 1 voted 25-3 to approve legislation that would provide $231.3 billion in funding for the departments of Labor, Health…
Headline
The AHA July 15 commented to Sens. Sheldon Whitehouse, D-R.I., and Bill Cassidy, R-La., responding to a request for information based on the Pay PCPs Act,…